Olaparib 150 MG

DRUG3 trials

Sponsors

Hospices Civils de Lyon, Azienda Ospedaliero-Universitaria di Modena, Boryung Pharmaceutical Co., Ltd

Conditions

Advanced Pancreatic CancerMetastatic Pancreatic CancerMutant High Grade GliomaOvarian CancerRecurrent IDH

Phase 1

A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer

RecruitingNCT07069335

Boryung Pharmaceutical Co., LtdOvarian Cancer

Start: 2025-06-17End: 2026-05-15Target: 24Updated: 2025-07-16

Phase 2

Olaparib in Recurrent IDH-mutant Glioma

CompletedNCT03561870

Hospices Civils de LyonMutant High Grade Glioma, Recurrent IDH

Start: 2019-03-20End: 2021-11-24Updated: 2025-09-12

Olaparib in PALB2 Advanced Pancreatic Cancer

RecruitingNCT06078787

Azienda Ospedaliero-Universitaria di ModenaAdvanced Pancreatic Cancer, Metastatic Pancreatic Cancer

Start: 2023-08-01End: 2026-08-01Target: 16Updated: 2024-05-06

Related Papers

Olaparib in recurrent IDH-mutant high-grade glioma (OLAGLI).

Journal of Clinical Oncology2021-05-2023 citations